Philosophe 2002.

Methods	RCT
Participants	Setting: Single centre Country: USA High risk for delayed graft function. First (92%) or second transplant. African‐Americans (63%) Age: NS ("similar for both groups") Sex: NS ("similar for both groups") Number (group 1/group 2): 50 (26/24)
Interventions	Treatment group 1 Daclizumab: 1 mg/kg day 0 and day 5 Treatment group 2 Muromonab‐CD3: administered for 7‐14 days Baseline immunosuppression TAC: NS MMF:NS Steroids: NS
Outcomes	Mortality Graft loss Acute rejection
Notes	1 year follow‐up On‐going study Data from abstracts
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Stated "randomized", no further information provided
Allocation concealment (selection bias)	Unclear risk	Not stated
Blinding (performance bias and detection bias) Objective outcomes	Unclear risk	Not stated
Blinding (performance bias and detection bias) Subjective outcomes	Unclear risk	Not stated
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Interim results only, results presented as percentages and unsure of numbers
Selective reporting (reporting bias)	Unclear risk	Interim 1 year results presented
Other bias	Unclear risk	Funding source not stated. Abstract only data available